Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 921 results for "gsk"

GSK and Theravance initiate global Phase III study for chronic obstructive pulmonary drug
Pharma Letter

Theravance : GSK and Theravance Introduce Initiation of Phase ...

GlaxoSmithKline plc and Theravance, Inc. reported the start of a global phase III study, known as IMPACT, to evaluate the efficacy and safety of the 'closed' triple combination of FF/UMEC/VI in patients with chronic obstructive pulmonary disease ... 4 Traders, 2 hours ago
[x]  

1,193 images for gsk

Sify, 16 hours ago
International Business Times UK, 3 days ago
Bidness Etc, 3 days ago
Yahoo! UK and Ireland, 16 hours ago
Fidelity Brokerage Services LLC, 4 days ago
Fidelity Brokerage Services LLC, 4 days ago
European CEO, 3 days ago
Bidness Etc, 6 days ago
Reuters India, 3 days ago
Marketing-interactive.com, 4 days ago
Yahoo! UK and Ireland

Eyes Down For GlaxoSmithKline plc Results

GlaxoSmithKline (LSE: GSK) (NYSE: GSK.US) has been overshadowed a bit of late by takeover attempts at rival AstraZeneca , and its share price has lagged a little -- it's been see-sawing all year and is down around 8% over the past 12 months, to ...
 Yahoo! UK and Ireland16 hours ago
China Post

2014 GSK Orange Day lets you 'Take a sip and fulfill children's dreams'

GSK Orange Day lets you 'Take a sip and fulfill children's dreams'TAIPEI, Taiwan -- GlaxoSmithKline (GSK) collaborated with the Child Welfare League Foundation (CWLF, 兒童福利聯盟文教基金會) again this year to help disadvantaged and ...
 China Post17 hours ago

GSK halts melanoma drug trial early after positive results

GlaxoSmithKline (GSK) has stopped its melanoma drug trial early after strong results to date were recorded. An independent data monitoring committee recommended that COMBI-v - a phase III study assessing a combination of GSK's Mekinist plus ...
 Pharma Field17 hours ago GSK melanoma trial stopped early  MedNous4 days ago
Pharmafocus

The Expert View: GlaxoSmithKline, Standard Chartered and British Land

More tough times are ahead for GlaxoSmithkline (GSK) as the pharmaceutical giant prepares to report is second quarter results on Wednesday, according to Panmure Gordon analyst Savvas Neophytou. In light of our recent downgrade to forecasts due to ...
 Wealth Manager1 day ago GSK melanoma drugs beat rival in new study  Pharmafocus3 days ago GLAXOSMITHKLINE : Melanoma Drug Study Shows Favorable Results  4 Traders4 days ago GlaxoSmithKline: Melanoma Drug Study Shows Favorable Results  Investors Hub3 days ago
[x]  

GSK Pharma — unhealthy trends

Here are some answers to readers queries on the performance of their stock holdings. Will Camlin Fine Sciences sustain at current levels? What is the outlook for it? Vageesh Camlin Fine Sciences (₹96.1): Following a sharp up move in the months ...
 Hindu Business Line1 day ago
Pharma Letter

GSK's phase III study of trametinib and dabrafenib combo shows survival benefit compared to vemurafenib

GlaxoSmithKline announced that the Independent Data Monitoring Committee (IDMC) recommended COMBI-v (MEK116513), a phase III study of its MEK inhibitor, trametinib (Mekinist), in combination with its BRAF inhibitor, dabrafenib (Tafinlar), compared ...
 PharmaBiz2 days ago IDMC Recommends GlaxoSmithKline 's Phase III Trial Of MEK/BRAF Combination  RTTNews.com4 days ago Trametinib (Mekinist) and dabrafenib (Tafinlar) combination demonstrated overall survival benefit compared to vemurafenib  European Pharmaceutical Review3 days ago Trametinib and dabrafenib gives overall survival benefit compared to vemurafenib  Pharma Letter4 days ago
[x]  
American Banking News

GlaxoSmithKline PLC (GSK) Showing Bearish Technicals With Support At $52.76

The patented option-trade picking algorithms that power MarketIntelligenceCenter.com's Artificial Intelligence Center are highlighting two trades on GlaxoSmithKline Plc (http://www.marketintelligencecenter.com/symbol/GSK"GSK) today after it closed ...
 Individual.com4 days ago GlaxoSmithKline plc's Hold Rating Reaffirmed at Panmure Gordon (GSK)  American Banking News3 days ago GlaxoSmithKline plc Rating Reiterated by Credit Suisse (GSK)  American Banking News3 days ago GlaxoSmithKline PLC (GSK) Trading Near $53.82 Resistance Level  Individual.com5 days ago
Bidness Etc

GSK Takes Another Hit As News Of 2001 Bribery Scandal Resurfaces

GSK's woes seem to be never-ending as the bribery investigations in China have unearthed a similar transgression over a decade agov Sign up for Daily Newsletter Sign Up Click Ticker to See live coverage GlaxoSmithKline plc (GSK) is in the ...
 Bidness Etc4 days ago Glaxo pleads guilty to 2001 Chinese bribery allegations  Seeking Alpha5 days ago GSK admits to bribing Chinese officials in 2001  European CEO4 days ago New scrutiny for GlaxoSmithKline after news of 2001 bribery-related housecleaning in China  FiercePharma4 days ago
[x]  
Himalayan times

AFP - China-Britain-US-court-crime-GSK

China-Britain-US-court-crime-GSK Contributed by NAMPA / AFP. China court pledges 'open trial' of foreign investigators SHANGHAI, July 17, 2014 (AFP) - The Shanghai court that will try two foreign investigators linked to the bribery case of ...
 Namibia Press Agency4 days ago Shanghai Court to Hold Open Trial for GSK Investigators  China Digital Times4 days ago China court pledges open trial of foreign investigators  Big News Network4 days ago China indicts GSK-linked foreign investigators: Xinhua  Himalayan times1 week ago
[x]  
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less